together with co-author and medicinal chemist jakob magolan, the team has developed new caffeine derivatives that potently lower blood pcsk9 levels, potentially leading to new ldl cholesterol treatments.
“we are excited to be pursuing this new class of medicines – or nutraceuticals – for the potential treatment and prevention of cardiovascular disease,” said magolan, associate professor in the department of biochemistry and biomedical sciences at mcmaster.
researchers are also exploring additional health benefits of caffeine and its derivatives beyond those observed in the present study.
“it is exciting to see yet another potential clinical benefit from caffeine,” said mark tarnopolsky, division head of neuromuscular and neurometabolic disorders at mcmaster’s department of pediatrics.
the study was co-led by austin and lebeau, from the hamilton centre for kidney research at the research institute of st. joe’s hamilton.
austin and lebeau’s team included researchers from several mcmaster university departments, as well as the libin cardiovascular institute of alberta at the university of calgary and the clinical research institute of montreal, affiliated with the university of montreal.
this article is republished from brighter world, mcmaster university under a creative commons license. read the original article.
thank you for your support. if you liked this story, please send it to a friend. every share counts.
share story
share this story
scientists discover how caffeine protects against cardiovascular disease